Related Experiment Video
Updated: Jun 3, 2026
In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
Published on: May 11, 2020
[Monoclonal antibodies to rubella virus glycoprotein E1]
Aim:
To obtain monoclonal antibodies (MCAs) to glycoprotein E1 of rubella virus, to assess their immunochemical characteristics and ability to use fluorescent MCA for rapid identification of rubella virus.
Materials And Methods:
Rubella virus strain C-74 (Moscow), vaccine strains "Orlov" (Saint-Petersburg), Wistar RA 27/3 (USA) as well as strain Judith (Germany) were used. Viral antigens were obtained using diploid cells L-68 and cell lines VNK-21-F and Vero E6. MCAs were produced by conventional method and their isotype was determined: Immunoblotting, immunoenzume assay (IEA), hemagglutination inhibition assay (HIA) and immunofluorescence assay (IFA) were performed.
Results:
Five monoclonal antibodies--Kh-252.1, Kh-347.2, Kh-183.3, Kh-214.4, Kh-187.5--to antigens of rubella virus strain C-74 were obtained. Isotypes of these antibodies were determined and their reactivity with native and denaturated antigens of other strains ("Orlov", Wistar RA 27/3, Judith) was characterized. IEA showed that all MCAs interacted with rubella virus glycoprotein E1 at high titers ranging from 1/1600 to 1/200,000. Immunoblotting demonstrated that 4 MCAs (Kh-252.1, Kh-347.2, Kh-183.3, Kh-214.4) had aforementioned feature. MCAs inhibited hemagglutinating activity of Judith strain in titer from 1/16 to 1/1024 in HIA. FITC conjugate of MCA Kh-347.2 (most sensitive variant) allowed to detect rubella virus in infected Vero E6 cells after 24 hours since infection, whereas FITC conjugates of 3 MCAs (Kh-183.3, Kh-214.4, Kh-187.5)--after 72 hours since infection.
Conclusion:
Use of FITC conjugates of MCAs is a perspective tool for identification of rubella virus glycoprotein E1 in infected cell cultures and nasopharyngeal swabs.
Insights
Researchers developed five monoclonal antibodies (MCAs) targeting rubella virus glycoprotein E1. These MCAs show promise for rapid rubella virus identification in cell cultures and clinical samples.
Area of Science:
- Virology
- Immunology
- Biotechnology
Background:
- Rubella virus causes significant congenital defects.
- Rapid and accurate diagnostics are crucial for rubella virus control.
- Monoclonal antibodies (MCAs) offer high specificity for viral antigens.
Purpose of the Study:
- To generate MCAs against rubella virus glycoprotein E1.
- To characterize the immunochemical properties of these MCAs.
- To evaluate their utility in rapid rubella virus detection.
Main Methods:
- Production of MCAs against rubella virus strain C-74.
- Characterization using immunoblotting, immunoenzyme assay (IEA), hemagglutination inhibition assay (HIA), and immunofluorescence assay (IFA).
- Testing reactivity with various rubella virus strains and antigens.
Main Results:
- Five MCAs (Kh-252.1, Kh-347.2, Kh-183.3, Kh-214.4, Kh-187.5) were successfully obtained.
- All MCAs recognized rubella virus glycoprotein E1 with high titers (1/1600–1/200,000) in IEA.
- FITC-conjugated MCAs enabled detection of rubella virus in infected cells within 24-72 hours.
Conclusions:
- MCAs against rubella virus glycoprotein E1 are effective diagnostic tools.
- FITC-conjugated MCAs provide a rapid method for rubella virus identification.
- This approach is valuable for infected cell cultures and nasopharyngeal swabs.
Related Concept Videos
01:29Respiratory Syncytial Virus Disease
00:42Cross-reactivity